Insider Sale Filed: Cyclacel Director Sells 19,054 Shares

Rhea-AI Filing Summary

Kua Khai Loon, identified on the form as a Director, reported a sale of 19,054 shares of Cyclacel Pharmaceuticals common stock on 09/05/2025 at a price of $7.01 per share. After the reported transaction the filing shows 385,411 shares beneficially owned, held directly. The Form 4 is signed and dated 09/10/2025. The filing discloses the transaction type as a sale and provides the transaction price and post-transaction holdings; no derivative transactions or additional explanatory details are included.

Positive

• Timely disclosure of an insider sale including transaction date, price, and post-transaction holdings
• Reporting person identified (Kua Khai Loon) and relationship to issuer (Director) are stated

Negative

• No explanation provided for the sale and no indication of a Rule 10b5-1 plan
• Materiality cannot be assessed from this Form 4 alone because outstanding share count or context is not provided

Insights

Securities Analyst

TL;DR: A director sold 19,054 shares at $7.01, leaving 385,411 shares; this routine disclosure is factual and provides transparency.

The Form 4 reports a straightforward insider sale with explicit quantities and price: 19,054 shares sold at $7.01 on 09/05/2025, reducing direct holdings to 385,411 shares. From a trading disclosure perspective, the filing meets Section 16 requirements by reporting the date, price, and post-transaction holdings. The document does not include any 10b5-1 plan checkbox or additional narrative explaining the rationale, and no derivative instruments are reported. Without context on total outstanding shares or recent trading patterns, the sale's relative materiality to valuation cannot be assessed from this filing alone.

Corporate Governance Expert

TL;DR: Insider complied with reporting requirements; sale by a director is disclosed but the filing supplies no explanation of intent.

The filing indicates compliance with required disclosure mechanics: reporter identity, relationship to issuer, transaction date, price, and resulting beneficial ownership are all stated. The reporting person is identified as a director. The absence of any checked box indicating a Rule 10b5-1 trading plan or other explanatory statement means the document contains no affirmative defense or stated pre-arrangement. For governance monitoring, this provides necessary transparency but does not explain whether the sale was routine, personal, or strategic.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kua Khai Loon

(Last) (First) (Middle)

NO 28 JALAN EKOFLORA 1/13 TAMAN EKOFLORA

(Street)

JOHOR BAHRU N8 81100

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cyclacel Pharmaceuticals, Inc. [ CYCC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/05/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/05/2025		S		19,054	D	$7.01	385,411	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Kua Khai Loon	09/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Kua Khai Loon report on the Form 4 for Cyclacel Pharmaceuticals (CYCCP)?

The Form 4 reports a sale of 19,054 shares of Cyclacel common stock on 09/05/2025 at $7.01 per share, with 385,411 shares beneficially owned afterward.

What is the reporting person's relationship to the issuer on this Form 4?

The filing identifies the reporting person, Kua Khai Loon, as a Director of the issuer.

Did the Form 4 disclose any derivative securities or option transactions?

No. Table II (derivative securities) contains no reported transactions or holdings in this filing.

Is there an indication this sale was made under a 10b5-1 trading plan?

No. The filing does not check or state any 10b5-1 plan or provide an explanation indicating such a plan.

When was the Form 4 signed?

The Form 4 bears the signature of the reporting person dated 09/10/2025.